Gilli Wei, Yulin Luo, Deuan Fu
Department of Thyroid and Breast Surgery, Jiangsu Norwegian Hospital, Yangzhou 225001, Jiangsu, People's Republic of China
* These authors contributed equally to this work
Purpose: To better elucidate the efficacy of neoadjuvant bevacizumab plus chemotherapy (BEV + CT) against chemotherapy (CT) alone in the treatment of HER2-negative non-metastatic breast cancer.
Methods: PubMed, Embase, Web of Science, and Cochrane Library databases, relevant articles were published from January 1, 2000 to July 31, 2018. The Review 5.3 software was used to perform this meta-analysis.
Results: Six randomized, controlled trials complied with the selection criteria, yielding a total of 4,354 patients with early outcomes and 3777 patients with end results. Total pathological complete response (pCR) and 5-year disease-free survival (DFS) were higher for the non-adjuvant BEV + CT group (OR = 1.37 [1.19, 1.58]; P<0.001 and HR = 0.84 [0.72, 0.98]; P= 0.020, respectively), but the 5-year total survival rate (OS) did not show a significant difference (HR = 0.79 [0.55, 1.11]; P= 0.180). Subgroup analysis showed that the rate of pCR was significantly higher in both subjects with positive hormone receptor (HR) breast cancer (OR = 1.30 [1.01, 1.66]; P= 0.040) and those with HR-negative breast cancer (OR = 1.52 [1.25, 1.83]; P<0.001) in the BEV + CT group.
Conclusion: Compared with CT alone, neoadjuvant BEV + CT significantly improves the 5-year DFS frequency of HER2-negative breast cancer patients but does not show any benefit in terms of 5-year OS.
Keywords: bevacizumab, neoadjuvant chemotherapy, breast cancer, HER2-negative, randomized controlled study
This work has been published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and include the Creative Commons Attribution – Noncommercial (unported, v3.0) license.
By accessing the work, you accept these Terms. Non-commercial use of the work is permitted without additional permission from Dove Medical Press Limited, provided the work is duly recorded. For permission to commercial use of this work, please refer to paragraphs 4.2 and 5 of our Terms.